Adis Drug Profile


, Volume 66, Issue 16, pp 2109-2119


  • Sheridan HennessAffiliated withWolters Kluwer Health / AdisWolters Kluwer Health Email author 
  • , Dean M. RobinsonAffiliated withWolters Kluwer Health / AdisWolters Kluwer Health
  • , Katherine A. Lyseng-WilliamsonAffiliated withWolters Kluwer Health / AdisWolters Kluwer Health

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


  • ▴ Rimonabant is the first of a new class of selective cannabinoid receptor-1 blockers. It reduces the overactivity of the endocannabinoid system, improving lipid and glucose metabolism and regulating food intake and energy balance.

  • ▴ In four randomised, double-blind clinical trials in overweight or obese adults with or without type 2 diabetes and/or dyslipidaemia, oral rimonabant 20mg once daily reduced weight and waist circumference to a significantly greater extent than placebo.

  • ▴ A significantly greater proportion of rimonabant than placebo recipients achieved the clinically significant weight-loss target of ≥5% or ≥10% of initial weight.

  • ▴ Rimonabant was associated with significant improvements in glycaemic control relative to placebo, with ≈57% of the reduction in glycosylated haemoglobin being independent of the effects of weight loss in one trial.

  • ▴ Improvements in other cardiometabolic risk factors (i.e. increases in high-density lipoprotein-cholesterol [HDL-C] and decreases in triglyceride [TG] levels) were significantly greater with rimonabant than with placebo.

  • ▴ The improvement in lipid profile also demonstrated a weight-independent effect, with ≈47–58% of the mprovement in HDL-C and TG being beyond that expected through weight loss alone.

  • ▴ Rimonabant was generally well tolerated, with most adverse events considered mild to moderate in severity.